Viewing nowBonviva Tablet 150 mg (Ibandronic Acid Sodium Hydrate)
Ibandronate Sodium Monohydrate 168.75mg
Tablet · Prescription medication
Jeil Pharmaceutical Co., Ltd.

MFDS item code 200607634 · Approved 2006.07.31 · Insurance code 645406240
Treatment of osteoporosis in postmenopausal women
This medication is used for the treatment of osteoporosis in postmenopausal women. It helps prevent the loss of bone density, strengthens bones, and reduces the risk of fractures. It aids in pain relief from osteoporosis and supports the maintenance of bone health for a healthier life.
Take 1 tablet once a month regularly, on the same morning each month, with plenty of water, at least 1 hour before consuming food, beverages (other than water), or other oral medicines or dietary supplements (including calcium): - This medicine should be swallowed with plenty of water (180-240ml) while standing or sitting upright, and the patient must not lie down for 60 minutes after taking it. - Take with plain water, as mineral water may reduce absorption of this medicine. - Do not chew or suck the tablet to avoid esophageal ulceration. If the patient forgets to take a dose on the scheduled day: - If 8 days or more remain until the next scheduled dose, take 1 tablet the next morning after realizing that the dose was missed, and thereafter take 1 tablet each month on the originally scheduled day. - If 7 days or fewer remain until the next scheduled dose, take 1 tablet on the next scheduled day, and thereafter take 1 tablet each month on the originally scheduled day. - Do not take 2 tablets in the same week. Patients with inadequate dietary intake should supplement with calcium or vitamin D, etc. Patients with hepatic impairment No dose adjustment is required. Patients with renal impairment No dose adjustment is required for patients with mild or moderate renal impairment and creatinine clearance of 30mL/min or higher. Administration of this medicine is not recommended for patients with creatinine clearance below 30mL/min because clinical experience is insufficient. Elderly patients No dose adjustment is required.
Efficacy and safety have not been studied in children 18 years of age or younger.
This medication should not be used in patients who have an allergic reaction to this drug or its other components. Furthermore, it should not be administered to patients with untreated hypocalcemia. Patients should remain in an upright position or sit for at least 60 minutes after taking this medication, and it is not suitable for patients who find it difficult to do so. Patients with esophageal dysfunction where food goes down poorly could be at risk when taking this drug. Since this medication contains lactose, patients with lactose intolerance or related genetic conditions should not take it. Caution is advised when administering this drug to patients with severe renal impairment, requiring medical judgment. Various side effects may occur during the use of this drug, including dyspepsia, nausea, abdominal pain, diarrhea, headache, muscle pain, joint pain, and rash. Flu-like symptoms such as fever, chills, and muscle aches may occur, especially at the beginning of treatment, but are usually temporary. Rarely, symptoms such as esophagitis, esophageal ulcers, dizziness, and low back pain may appear; if severe symptoms arise, it is advisable to consult with a healthcare provider. This drug can cause severe side effects such as inflammation of the eyes or jaw osteonecrosis, hence reporting any unusual symptoms immediately is crucial. If dental treatment is required, an oral examination should be conducted before use, and excessive dental treatment during the course of treatment is recommended to be avoided. This drug may interfere with absorption when taken with food or products containing calcium, magnesium, iron, etc., so it is recommended not to consume any other food or medication for at least 1 hour after taking it. Pregnant or breastfeeding women should avoid using this drug for safety. Older adults can use it without dosage adjustment, but safety and efficacy have not been established in children. Overdose may result in gastrointestinal disturbances or hypocalcemia, necessitating the maintenance of a standing position and immediate visit to a medical institution without inducing vomiting. This drug should be stored out of reach of children, and unused medication should be disposed of properly to prevent environmental contamination.
Dyspepsia, nausea, abdominal pain, diarrhea, distension, gastroesophageal reflux disease, headache, influenza-like illness, fatigue, myalgia, arthralgia, rash, gastritis, esophagitis, muscle cramps, musculoskeletal pain, musculoskeletal stiffness, dysphagia, vomiting, esophageal ulcer, esophageal stricture, dizziness, low back pain, duodenitis, hypersensitivity reactions, angioedema, facial swelling, urticaria, uveitis, scleritis, osteonecrosis of the jaw and external auditory canal, anaphylactic reaction, shock, exacerbation of asthma, allergic reactions, Stevens-Johnson syndrome, erythema multiforme, vesicular dermatitis, atypical subtrochanteric fracture, intertrochanteric femoral fracture, abnormal sensation in the eyes, weakness, pruritus
Not everyone experiences these, and they can vary from person to person.
This medication should be kept in a tightly sealed container to prevent exposure to air or moisture and stored at room temperature between 1 to 30 degrees Celsius. Proper storage helps maintain the effectiveness of the drug.
White to almost white rectangular film-coated tablets
1 tablet / PTP
Even with the same ingredient, strength, dosage form and how it is taken can differ.
Viewing nowIbandronate Sodium Monohydrate 168.75mg
Tablet · Prescription medication
Jeil Pharmaceutical Co., Ltd.
Ibandronate Sodium Monohydrate 3.375mg
Solution · Prescription medication
Jeil Pharmaceutical Co., Ltd.

Ibandronate Sodium Monohydrate 168.75mg
Tablet · Prescription medication
Chodang Pharmaceutical Co., Ltd.

Ibandronate Sodium Monohydrate 168.75mg
Tablet · Prescription medication
Shinpoong Pharmaceutical Co., Ltd.

Ibandronate Sodium Monohydrate 168.75mg
Tablet · Prescription medication
Ajou Pharmaceutical Co., Ltd.

Ibandronate Sodium Monohydrate 168.75mg
Tablet · Prescription medication
Aliko Pharmaceutical Co., Ltd.

Ibandronate Sodium Monohydrate 168.75mg
Tablet · Prescription medication
Teragen Etex Co., Ltd.

Ibandronate Sodium Monohydrate 168.75mg
Tablet · Prescription medication
Huons Co., Ltd.
Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.